The results of this study also indicated that cancer cells secreting high levels of FGF21 were resistant to anti-PD-1 monotherapy, whereas the combination of anti-FGF21 and anti-PD-1 therapies showed significant anti-cancer effects.7 The gene discussed is FGF21; the disease is cancer.